Quantifying Intangibles: Operating Model Assumptions In Biotech Valuation
DOI:
https://doi.org/10.29284/aesa3d85Keywords:
Biotech Valuation, Intangible Assets, Operating Model Assumptions, Risk-Adjusted NPV (rNPV), Real Options Analysis.Abstract
Valuing biotechnology companies presents distinct challenges due to their reliance on intangible assets, such as intellectual property, early-stage research pipelines, regulatory milestones, and specialized human capital. Unlike firms in traditional sectors with steady cash flows and tangible assets, biotech companies often operate in pre-revenue or early-revenue stages, making valuation highly sensitive to subjective model assumptions. These include probabilities of success for drug development, time-to-market forecasts, cost of capital, and expectations around licensing and commercialization revenues.
This review examines how such assumptions are incorporated into biotech valuation frameworks, focusing on methods like discounted cash flow (DCF), risk-adjusted net present value (rNPV), and real options analysis. It evaluates the influence of variables such as R&D expenditure, clinical trial outcomes, regulatory pathways, and go-to-market strategies on model accuracy and investment decision-making. The paper also explores how practitioners quantify intangible drivers, ranging from patents and platform technologies to early-stage data and scientific expertise, within valuation models. It assesses the role of strategic alliances, licensing agreements, and M&A transactions as market-based indicators of underlying asset value. Techniques such as Monte Carlo simulations, probability-weighted forecasting, and external benchmarking are discussed as tools to better manage uncertainty and refine model robustness. In addition, the review addresses accounting and regulatory considerations, sector-specific risks, and the limitations of traditional financial reporting in capturing biotech value. It highlights emerging applications of machine learning and data analytics for predicting clinical and financial outcomes. The paper concludes by identifying research gaps and offering recommendations for improving transparency, standardizing assumptions, and integrating qualitative judgment with quantitative rigor. This review provides analysts, investors, and life science professionals with a structured perspective on designing valuation models that meaningfully account for the intangible and uncertain nature of biotech enterprises.
References
1. Nelson, T. R., & Mukherji, A. (1998). Valuing biotechnology assets. Nature biotechnology, 16(6), 525–529.
2. Segnani, M., & Ferrari, E. (2018). The determinants of venture capital pre-money valuation: the case of European biotechnology startups.
3. Copeland, T. (2001). Real Options: A Practitioner's Guide. Texere LLC.
4. Pisano, G. P. (2006). Science business: The promise, the reality, and the future of biotech. Harvard Business Press.
5. Lev, B. (2000). Intangibles: Management, measurement, and reporting. Bloomsbury Publishing USA.
6. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature reviews Drug discovery, 8(12), 959–968.
7. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics, 47, 20–33.
8. Cockburn, I. M., & Henderson, R. M. (2001). Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of health economics, 20(6), 1033–1057.
9. Koller, T., Goedhart, M., & Wessels, D. (2010). Valuation: measuring and managing the value of companies. John Wiley & Sons.
10. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery, 9(3), 203–214.
11. Hall, B. H., & Lerner, J. (2010). The financing of R&D and innovation. In Handbook of the Economics of Innovation (Vol. 1, pp. 609–639). North-Holland.
12. Woo, J., Kim, E., Sung, T. E., Lee, J., Shin, K., & Lee, J. (2019). Developing an improved risk-adjusted net present value technology valuation model for the biopharmaceutical industry. Journal of Open Innovation: Technology, Market, and Complexity, 5(3), 45.
13. Arora, A., Fosfuri, A., & Gambardella, A. (2004). Markets for technology: The economics of innovation and corporate strategy. MIT Press.
14. Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. Administrative science quarterly, 35(1), 128–152.
15. Ernst, Y., & Young, T. (2006). Beyond borders: Global biotechnology report 2006. Back on Track – The European Perspective.
16. Dixit, A. K. (1994). Investment under uncertainty. Princeton University Press.
17. Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemporary clinical trials communications, 11, 156–164.
18. De Backer, R., Ruby, T., & Saxena, A. (2017). Biopharma Valuations, Onward and upward.
19. Deloitte, L. (2013). Measuring the return from pharmaceutical innovation 2013. Weathering the storm, 1–35.
20. Glasserman, P. (2004). Monte Carlo methods in financial engineering (Vol. 53). New York: Springer.
21. Hull, J. C., & Basu, S. (2016). Options, futures, and other derivatives. Pearson Education India.
22. Beynon, K., & Porter, A. (2000). Valuing pharmaceutical companies: A guide to the assessment and evaluation of assets, performance and prospects. Woodhead Publishing.
23. Rydzewski, R. M. (2010). Real world drug discovery: A chemist's guide to biotech and pharmaceutical research. Elsevier.
24. Bergeron, B., & Chan, P. (2004). Biotech industry: A global, economic, and financing overview. John Wiley & Sons.
25. Araja, D. (2023). Insights into trends and challenges of the pharmaceutical industry: the role of scientific business research. Journal of Business Management, 21, 48–63.
26. An, I. M. A. P. (2011). Pharmaceuticals & Biotech Industry Global Report—2011.
27. Dharmamoorthy, G., Sabareesh, M., Balaji, A., Dharaniprasad, P., & Swetha, T. (2022). An overview on top 10 pharma industry trends and innovations 2022. YMER Journal, 21(11), 2123–2140.
28. Yuyan, G. (2023). A financial analysis report of three typical biopharmaceutical companies in UK. Academic Journal of Business & Management, 5(1), 165–170.
29. Heinonen, M. (2002). Disclosure of the dealings between drug developing companies and the FDA under the federal securities laws.
30. Fisher, W. O. (2001). Key disclosure issues for life sciences companies: FDA product approval, clinical test results, and government inspections. Mich. Telecomm. & Tech. L. Rev., 8, 115.
31. Topol, E. (2019). Deep medicine: how artificial intelligence can make healthcare human again. Hachette UK.
32. Nyiramana Mukamurera, P. (2024). The role of artificial intelligence in clinical decision support systems. Research Invention Journal of Public Health and Pharmacy, 3(2), 14–17.
33. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. Nature medicine, 25(1), 24–29.
34. Kreimeyer, K., Foster, M., Pandey, A., et al. (2017). Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. Journal of biomedical informatics, 73, 14–29.
35. U.S. Food and Drug Administration (FDA). Framework for FDA's real-world evidence program. 2018.
36. Galindo-Rueda, F. (2013). The OECD measurement agenda for innovation. In Handbook of innovation indicators and measurement (pp. 217–246). Edward Elgar Publishing.
37. DiMasi, J. A., & Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics, 28(4–5), 469–479.
38. Nicotera, G., Sferrazza, G., Serafino, A., & Pierimarchi, P. (2019). The iterative development of medicines through the European Medicine Agency's adaptive pathway approach. Frontiers in Medicine, 6, 148.
39. Francisco, M., & Linnér, B. O. (2023). AI and the governance of sustainable development. An idea analysis of the European Union, the United Nations, and the World Economic Forum. Environmental Science & Policy, 150, 103590.
40. Lazonick, W., & Tulum, Ö. (2011). US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy, 40(9), 1170–1187.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
